Johnson & Johnson

Immunomodulatory agents, monoclonal antibodies, bispecific antibodies, and CAR T-cell therapy have transformed multiple myeloma treatment. Despite improvements, MM remains incurable, prompting research into protein degradation and immune system activation. The triSpecific antibody JNJ-79635322 targets BCMA, GPRC5D, and CD3, showing promise in preclinical trials. Other approaches include BCMA-targeting ADCs like belantamab mafodotin and small molecule E3 ligase modulators like mezigdomide, aiming to enhance immunotherapies and prolong patient survival.

MP Nigdelis received honoraria from RG Ärztefortbildung GmbH and travel grants from Organon and Gedeon Richter. M Doerk received travel grants from Gedeon Richter, Organon, and Eisai, and is a member of DGGG, AGE, and Deutsche Gesellschaft für Senologie. S Burghaus received honoraria from FOMF and is a member of DGGG, AGEM, AGE, Stiftung Endometriose Forschung, AGUB, AGO, and DKK. M Sillem, CEO of EuroEndoCert Gmbh, received payments from Bayer, Gedeon Richter, Hologic, and EndoHealth. B Haj Hamoud received travel grants from Gedeon Richter, Astrazeneca, Johnson & Johnson, and Storz, and is a member of DGGG, AGE, and Stiftung Endometriose Forschung. EF Solomayer receives grants from the University of Saarland, Storz, and Erbe, and fees from Roche, Pfizer, Celgene, Amgen, Astra Zeneca, Esai, Johnson & Johnson, Novartis, Tesaro, Teva, Medac GmbH, MSD, Vifor, Gedeon Richter, Takeda, and AGE, among others. GL Olmes received grants from AstraZeneca, Universitätsklinikum Freiburg, and RG Ärztefortbildung GmbH, and is a member of DGGG, AGE, and AGEM, with scientific collaboration with Karl Stotz.

CARTITUDE-4 trial data at IMS 2024 shows cilta-cel significantly improves overall survival (HR .55) and progression-free survival (HR .29) in lenalidomide-refractory multiple myeloma patients, with no new safety concerns.

CARVYKTI® reduces death risk by 45% in lenalidomide-refractory multiple myeloma patients, significantly extending overall survival in the CARTITUDE-4 study, presented at the 2024 International Myeloma Society Annual Meeting.

FDA approves Formycon AG's biosimilar FYB202/OtulfiTM (ustekinumab-aauz) for treating Crohn’s disease, ulcerative colitis, moderate-to-severe plaque psoriasis, and active psoriatic arthritis.

Amivantamab (Rybrevant) has received 3 FDA approvals for EGFR-mutated non–small cell lung cancer (NSCLC), including first-line use in EGFR exon 20 insertion mutations, a chemotherapy-free regimen with lazertinib for exon 19 deletions or exon 21 L858R mutations, and with standard chemotherapy for patients with exon 19 deletions or exon 21 L858R mutations post-EGFR TKI treatment. The MARIPOSA trial evaluated amivantamab plus lazertinib versus osimertinib, showing superior progression-free survival.

Johnson & Johnson's darzalex faspro treatment showed 60.9% improvement in eliminating cancer cells and 43% reduction in progression or death for newly diagnosed multiple myeloma patients in Cepheus phase 3 trial.

Talquetamab, a bispecific GPRC5D-directed CD3 T-cell engager, demonstrated durable responses in multiple myeloma patients with 4-5 prior therapies in TRIMM-2 and RedirecTT trials. Updated phase 1b results showed an 81.8% ORR and 15.5-month median PFS in the TRIMM-2 triplet arm, and a 79.5% ORR at 18 months in the RedirecTT-1 dual bispecific arm. Both combinations showed robust durability and efficacy, even in high-risk patients with extramedullary disease.

The CEPHEUS trial showed that adding daratumumab to the VRd regimen improved MRD negativity rates to 60.9% vs 39.4% with VRd alone in newly diagnosed multiple myeloma patients ineligible for or deferred transplant, with a CR or better rate of 81.2% vs 61.6%. The subcutaneous daratumumab-based regimen demonstrated deep, durable responses and reduced disease progression risk, potentially becoming a new standard for this patient population.

DARZALEX FASPRO® in maintenance therapy significantly increased MRD-negativity rate at 12 months compared to lenalidomide alone, improving 30-month progression-free survival in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant.